These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

290 related items for PubMed ID: 18092426

  • 1. COPD: don't use fluticasone + salmeterol. Patients treated with inhaled fluticasone for chronic obstructive pulmonary disease (COPD) are more prone to pneumonia.
    Prescrire Int; 2007 Dec; 16(92):257-8. PubMed ID: 18092426
    [No Abstract] [Full Text] [Related]

  • 2. Fluticasone/salmeterol: labeling change.
    Prescrire Int; 2008 Dec; 17(98):229. PubMed ID: 19418648
    [Abstract] [Full Text] [Related]

  • 3. Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations.
    Ferguson GT, Anzueto A, Fei R, Emmett A, Knobil K, Kalberg C.
    Respir Med; 2008 Aug; 102(8):1099-108. PubMed ID: 18614347
    [Abstract] [Full Text] [Related]

  • 4. The efficacy and safety of inhaled fluticasone propionate/salmeterol and ipratropium/albuterol for the treatment of chronic obstructive pulmonary disease: an eight-week, multicenter, randomized, double-blind, double-dummy, parallel-group study.
    Make B, Hanania NA, ZuWallack R, Kalberg C, Emmett A, Brown CP, Knobil K.
    Clin Ther; 2005 May; 27(5):531-42. PubMed ID: 15978302
    [Abstract] [Full Text] [Related]

  • 5. Lower inhaled steroid requirement with a fluticasone/salmeterol combination in family practice patients with asthma or COPD.
    Schermer TR, Albers JM, Verblackt HW, Costongs RJ, Westers P.
    Fam Pract; 2007 Apr; 24(2):181-8. PubMed ID: 17251178
    [Abstract] [Full Text] [Related]

  • 6. Prevention of death in COPD.
    Duerden M.
    N Engl J Med; 2007 May 24; 356(21):2212; author reply 2213-4. PubMed ID: 17526087
    [No Abstract] [Full Text] [Related]

  • 7. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease.
    Kardos P, Wencker M, Glaab T, Vogelmeier C.
    Am J Respir Crit Care Med; 2007 Jan 15; 175(2):144-9. PubMed ID: 17053207
    [Abstract] [Full Text] [Related]

  • 8. Changes in lung function and health status in patients with COPD treated with tiotropium or salmeterol plus fluticasone.
    Kurashima K, Hara K, Yoneda K, Kanauchi T, Kagiyama N, Tokunaga D, Takayanagi N, Ubukata M, Sugita Y.
    Respirology; 2009 Mar 15; 14(2):239-44. PubMed ID: 19210650
    [Abstract] [Full Text] [Related]

  • 9. Predictive factors for evaluation of response to fluticasone propionate/salmeterol combination in severe COPD.
    Tonnel AB, Tillie-Leblond I, Attali V, Bavelele Z, Lagrange O.
    Respir Med; 2011 Feb 15; 105(2):250-8. PubMed ID: 20702076
    [Abstract] [Full Text] [Related]

  • 10. Combined salmeterol and fluticasone for COPD.
    Vassiliou V.
    Lancet; 2003 May 10; 361(9369):1651; author reply 1652-3. PubMed ID: 12747901
    [No Abstract] [Full Text] [Related]

  • 11. Combination therapy in COPD: different response of COPD stages and predictivity of functional parameters.
    Terzano C, Petroianni A, Ricci A, Allegra L.
    Eur Rev Med Pharmacol Sci; 2005 May 10; 9(4):209-15. PubMed ID: 16128040
    [Abstract] [Full Text] [Related]

  • 12. [Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial].
    Wouters EF, Postma DS, Fokkens B, Hop WC, Prins J, Kuipers AF, Pasma HR, Hensing CA, Creutzberg EC, Cosmic COPD and Serentide: A Multi-Center Intervention and Characterization Study Group.
    Rev Port Pneumol; 2005 May 10; 11(6):587-9. PubMed ID: 16514718
    [No Abstract] [Full Text] [Related]

  • 13. [Debates surrounding COPD].
    Tillie-Leblond I, Housset B.
    Rev Mal Respir; 2010 Feb 10; 27(2):106-7. PubMed ID: 20206057
    [No Abstract] [Full Text] [Related]

  • 14. Effects of adding salmeterol/fluticasone propionate to tiotropium on airway dimensions in patients with chronic obstructive pulmonary disease.
    Hoshino M, Ohtawa J.
    Respirology; 2011 Jan 10; 16(1):95-101. PubMed ID: 20920142
    [Abstract] [Full Text] [Related]

  • 15. Cost-effectiveness of salmeterol, fluticasone, and combination therapy for COPD.
    Oba Y.
    Am J Manag Care; 2009 Apr 10; 15(4):226-32. PubMed ID: 19355795
    [Abstract] [Full Text] [Related]

  • 16. [Salmeterol + fluticasone in COPD. Complementary treatment principles hold true in the COPD management, too].
    MMW Fortschr Med; 2003 Nov 13; 145(46):47. PubMed ID: 14699834
    [No Abstract] [Full Text] [Related]

  • 17. Comparison of hospitalizations, emergency department visits, and costs in a historical cohort of Texas Medicaid patients with chronic obstructive pulmonary disease, by initial medication regimen.
    Rascati KL, Akazawa M, Johnsrud M, Stanford RH, Blanchette CM.
    Clin Ther; 2007 Jun 13; 29(6):1203-13. PubMed ID: 17692734
    [Abstract] [Full Text] [Related]

  • 18. Prevention of death in COPD.
    Kupfer Y, Tessler S.
    N Engl J Med; 2007 May 24; 356(21):2212-3; author reply 2213-4. PubMed ID: 17526086
    [No Abstract] [Full Text] [Related]

  • 19. Combined salmeterol and fluticasone for COPD.
    Khamis RY, Rajakulasingam RK.
    Lancet; 2003 May 10; 361(9369):1652; author reply 1652-3. PubMed ID: 12747905
    [No Abstract] [Full Text] [Related]

  • 20. Reflections on TORCH: potential mechanisms for the survival benefit of salmeterol/fluticasone propionate in COPD patients.
    Johnson M, Agusti AG, Barnes NC.
    COPD; 2008 Dec 10; 5(6):369-75. PubMed ID: 19353351
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.